Melissa R. Snyder
Research Subjects
Melissa R. Snyder has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Maria Alice Vieira Willrich
Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN
3 shared publications - Paula Marie Ladwig
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
2 shared publications Sarah M. Jenkins
Mayo Clin, Dept Quantitat Hlth Sci, Div Clin Trials & Biostat, Rochester, MN USA
2 shared publicationsAlicia Algeciras-Schimnich
Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
1 shared publication- Angela Dispenzieri
Division of Hematology, Mayo Clinic, Rochester, USA
1 shared publication - Anne E. Tebo
Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN
1 shared publication
Latest Publications
- 3 February 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 71 (2) , 253
Commentary on Hiding in Plain Sight: Protein Electrophoresis Profile Inconsistent with Patient’s Diagnosis
- 3 February 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 71 (2) , 253
Commentary on Hiding in Plain Sight: Protein Electrophoresis Profile Inconsistent with Patient’s Diagnosis
- 1 February 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (5) , 412-419
Historical Perspective on Antinuclear Antibody Testing
Serum factors binding to cell nuclei were first described in the 1940s, and the antibodies responsible for the binding to self (autoantibodies) were discovered in the late 1950s. Routine standardized testing using a cell line (HEp-2) started in the 1980s and continues to evolve. In addition to the classic immunofluorescence assay (IFA), various immunochemical techniques have been developed for the measurement of antinuclear antibodies (ANAs). The complexity of ANA IFA pattern reading and the varying sensitivities, specificities, and overall clinical performance of the alternative methods have often generated controversies and sometimes even confusion among healthcare providers and laboratorians. A better understanding of the historical roots of ANA testing can aid in understanding these controversies and assist with selecting the best-performing methods. In this review, we present historic and contemporary ANA testing methods, highlighting the pros and cons of each. We also provide an overview of the current practice of ANA testing based on several recent large laboratory surveys. For optimal patient care, it is critical that clinicians and laboratorians using ANA testing understand the performance and limitations of the methods used by their institutions, as well as the meaning of the test results. Recently published surveys and standardization efforts initiated by several stakeholder scientific organizations will likely lead to new ANA diagnostic guidelines, to be followed by an improvement in testing practices, management, and outcomes for patients with autoimmune disorders.
- 1 February 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (5) , 412-419
Historical Perspective on Antinuclear Antibody Testing
Serum factors binding to cell nuclei were first described in the 1940s, and the antibodies responsible for the binding to self (autoantibodies) were discovered in the late 1950s. Routine standardized testing using a cell line (HEp-2) started in the 1980s and continues to evolve. In addition to the classic immunofluorescence assay (IFA), various immunochemical techniques have been developed for the measurement of antinuclear antibodies (ANAs). The complexity of ANA IFA pattern reading and the varying sensitivities, specificities, and overall clinical performance of the alternative methods have often generated controversies and sometimes even confusion among healthcare providers and laboratorians. A better understanding of the historical roots of ANA testing can aid in understanding these controversies and assist with selecting the best-performing methods. In this review, we present historic and contemporary ANA testing methods, highlighting the pros and cons of each. We also provide an overview of the current practice of ANA testing based on several recent large laboratory surveys. For optimal patient care, it is critical that clinicians and laboratorians using ANA testing understand the performance and limitations of the methods used by their institutions, as well as the meaning of the test results. Recently published surveys and standardization efforts initiated by several stakeholder scientific organizations will likely lead to new ANA diagnostic guidelines, to be followed by an improvement in testing practices, management, and outcomes for patients with autoimmune disorders.
- Open Access
- 25 January 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 136, 110890
Evaluation of an automated assay for eosinophil-derived neurotoxin in serum
- 25 January 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 136, 110890
Open AccessEvaluation of an automated assay for eosinophil-derived neurotoxin in serum
- 15 November 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 121-122, 110685
Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays
- 15 November 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 121-122, 110685
Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays
- Open Access
- 26 July 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 119, 110618
Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
- 26 July 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 119, 110618
Open AccessOutcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
- 20 June 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (9) , 2070-2074
Anti‐phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all‐comer population
- 20 June 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (9) , 2070-2074
Anti‐phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all‐comer population
- Open Access
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 3510
Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Introduction: Primary cold agglutinin disease (CAD) is a rare disorder and accounts for 15% of all autoimmune hemolytic anemia. It is associated with an underlying monoclonal protein, which is IgM kappa in the majority of patients. The IgM protein triggers complement mediated extravascular hemolysis. The underlying pathophysiology by which autoimmune hemolysis affects only a small subset of patients with IgM monoclonal protein is poorly understood. Changes in the IgM structure via post-translational modifications of light chains (LCs), such as glycosylation are enriched in patients with AL amyloidosis, another rare disorder where disease manifestations are driven by the protein structure. (Kumar S et al Leukemia 2017). We hypothesized that presence of post-translational glycosylation is a potential mechanism allowing the IgM protein to trigger complement mediated hemolysis in CAD. Methods: Serum samples of patients being evaluated for monoclonal protein disorders were analyzed by immuno-enrichment-based matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS), termed MASS-FIX. Patients who had an underlying IgM monoclonal protein identified by MASS-FIX from 07/23/2018 to 5/14/2019 were included this study. Glycosylated LCs were identified by the shift in their molecular mass due to the added molecular mass of the carbohydrates. Glycosylation was compared in patients with IgM associated CAD vs. other IgM disorders. Results: 438 unique patients with an IgM monoclonal protein identified on MASS-FIX were included in the study. CAD was present in 3% (n=14) of patients. The primary underlying diagnosis in the remaining patients was monoclonal gammopathy of undetermined significance (MGUS): 47% (n=206), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM): 30% (n=132), non-LPL lymphoma: 6% (n=28), AL amyloidosis: 4% (n=19), CLL: 4% (n=18), cryoglobulinemia: 2% (n=10), multiple myeloma: 2% (n=9) and other: 0.5% (n=2) Glycosylation was present in 7% (31/438) of patients in this cohort. Glycosylation was significantly more prevalent in patients with CAD than other IgM gammopathies (64% vs. 5%, p Conclusions: Modification of the IgM immunoglobulin structure by post-translational glycosylation of LCs was significantly more common in patients with CAD compared with other IgM monoclonal gammopathies (64% vs. 5%, p <0.001). CAD was seen in only 1% of patients without glycosylation, while one-third of patients with glycosylation had CAD. This is a novel finding. As MASS FIX is now routinely done for detection of monoclonal proteins at our institution, the presence of LC glycosylation can provide diagnostic clues and can be a potential therapeutic target in the future. Future studies in larger, independent cohorts of patients are needed to confirm these findings. *SS & DLM contributed equally
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 3510
Open AccessGlycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Introduction: Primary cold agglutinin disease (CAD) is a rare disorder and accounts for 15% of all autoimmune hemolytic anemia. It is associated with an underlying monoclonal protein, which is IgM kappa in the majority of patients. The IgM protein triggers complement mediated extravascular hemolysis. The underlying pathophysiology by which autoimmune hemolysis affects only a small subset of patients with IgM monoclonal protein is poorly understood. Changes in the IgM structure via post-translational modifications of light chains (LCs), such as glycosylation are enriched in patients with AL amyloidosis, another rare disorder where disease manifestations are driven by the protein structure. (Kumar S et al Leukemia 2017). We hypothesized that presence of post-translational glycosylation is a potential mechanism allowing the IgM protein to trigger complement mediated hemolysis in CAD. Methods: Serum samples of patients being evaluated for monoclonal protein disorders were analyzed by immuno-enrichment-based matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS), termed MASS-FIX. Patients who had an underlying IgM monoclonal protein identified by MASS-FIX from 07/23/2018 to 5/14/2019 were included this study. Glycosylated LCs were identified by the shift in their molecular mass due to the added molecular mass of the carbohydrates. Glycosylation was compared in patients with IgM associated CAD vs. other IgM disorders. Results: 438 unique patients with an IgM monoclonal protein identified on MASS-FIX were included in the study. CAD was present in 3% (n=14) of patients. The primary underlying diagnosis in the remaining patients was monoclonal gammopathy of undetermined significance (MGUS): 47% (n=206), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM): 30% (n=132), non-LPL lymphoma: 6% (n=28), AL amyloidosis: 4% (n=19), CLL: 4% (n=18), cryoglobulinemia: 2% (n=10), multiple myeloma: 2% (n=9) and other: 0.5% (n=2) Glycosylation was present in 7% (31/438) of patients in this cohort. Glycosylation was significantly more prevalent in patients with CAD than other IgM gammopathies (64% vs. 5%, p Conclusions: Modification of the IgM immunoglobulin structure by post-translational glycosylation of LCs was significantly more common in patients with CAD compared with other IgM monoclonal gammopathies (64% vs. 5%, p <0.001). CAD was seen in only 1% of patients without glycosylation, while one-third of patients with glycosylation had CAD. This is a novel finding. As MASS FIX is now routinely done for detection of monoclonal proteins at our institution, the presence of LC glycosylation can provide diagnostic clues and can be a potential therapeutic target in the future. Future studies in larger, independent cohorts of patients are needed to confirm these findings. *SS & DLM contributed equally